A Surprising Effect in Cancer Care
Imagine a patient with lung cancer. Doctors target one tumor with radiation or ablation. A few weeks later, a scan shows that not only did the treated tumor shrink, but other tumors in different parts of the body also got smaller.
This is not science fiction. It’s a real phenomenon called the abscopal effect. The name comes from Latin words meaning “away from the target.” It means that treating one spot can cause tumors far away to shrink too.
This effect has been known since the 1950s, but it was considered very rare. Now, with new cancer treatments, doctors are seeing it more often.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It accounts for about 85% of all lung cancer cases. Many patients have tumors that have spread beyond the lungs.
Current treatments include surgery, radiation, and chemotherapy. Newer treatments called immunotherapy help the body’s own immune system fight cancer. But for many patients, these treatments are not enough.
The abscopal effect offers a new hope. It suggests that combining local treatments (like radiation or ablation) with immunotherapy could help the immune system attack cancer throughout the body.
The Old Way vs. The New Way
For decades, doctors focused on treating each tumor individually. If a patient had tumors in the lung and liver, each tumor was treated separately. The idea that treating one tumor could affect another was not part of the plan.
But here’s the twist: New research shows that the immune system can be trained to recognize and attack cancer cells everywhere. When a tumor is treated with radiation or ablation, it releases signals that alert the immune system. These signals act like a flare gun, telling the body to look for and destroy other cancer cells.
This changes how we think about cancer treatment. Instead of just targeting tumors, we can now think about boosting the whole immune system.
How It Works: A Simple Analogy
Think of your immune system as a security guard patrolling a building. Cancer cells are like intruders hiding in different rooms. Normally, the security guard might not notice the intruders if they are quiet.
When you treat one tumor with radiation or ablation, it’s like setting off a loud alarm in one room. The noise gets the security guard’s attention. Now, the guard is on high alert and starts checking all the rooms. This is how treating one tumor can lead to finding and removing other tumors too.
This process is called immunogenic cell death. It’s when cancer cells die in a way that sends out danger signals. These signals wake up the immune system and make it better at finding and killing cancer cells.
A new review in Frontiers in Medicine looked at all the current evidence on the abscopal effect in NSCLC. The authors reviewed studies from labs and early human trials.
They found that combining local treatments (like radiation or ablation) with immunotherapy can increase the chances of the abscopal effect. But the effect is still not well understood. Many clinical trials do not even look for it.
The review also found that the way we measure tumor responses (called RECIST criteria) may miss the abscopal effect. These criteria focus on treated tumors and may not capture shrinkage in untreated tumors.
A New Definition for a New Era
To help doctors and researchers, the review proposes a clear definition of the abscopal effect in NSCLC. It is defined as:
- The shrinkage (complete or partial response) of one or more untreated tumors
- That are far from the treated tumor
- Happening after local therapy (with or without immunotherapy)
- Confirmed by follow-up scans within 4 to 8 weeks
This definition will help standardize how the abscopal effect is identified and studied.
But There’s a Catch
Most of the evidence comes from small studies or lab models. Large, controlled trials are still needed. The abscopal effect is not yet a standard part of lung cancer treatment.
Also, not all patients will experience this effect. It depends on many factors, including the type of tumor and the patient’s immune system.
What Experts Say
The authors of the review stress that the abscopal effect is a promising area of research. They believe that with better tools to measure it, we can learn how to make it happen more often.
They also say that the abscopal effect is just one part of a bigger picture. The goal is to use the immune system to control cancer long-term.
If you or a loved one has NSCLC, this research is encouraging. It shows that new treatment combinations are being explored that could help more patients.
This doesn’t mean this treatment is available yet.
Talk to your doctor about the latest treatments and clinical trials. Ask if combining local therapy with immunotherapy might be an option for you.
The next step is to design clinical trials that specifically look for the abscopal effect. Researchers need to use the new definition and better imaging tools to capture these responses.
It will take time to see if these treatments become standard. But the review gives a clear path forward. By understanding and measuring the abscopal effect, we can move closer to using the immune system to fight lung cancer more effectively.